Literature DB >> 24740195

The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Jeffrey J Olson1, Lakshmi Nayak, D Ryan Ormond, Patrick Y Wen, Steven N Kalkanis, Timothy Charles Ryken.   

Abstract

QUESTION: What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma? TARGETED POPULATION: This recommendation applies to adult patients with progressive glioblastoma RECOMMENDATIONS: Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24740195     DOI： 10.1007/s11060-013-1339-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  155 in total

1.  Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Authors:  Christine E Brown; Renate Starr; Brenda Aguilar; Andrew F Shami; Catalina Martinez; Massimo D'Apuzzo; Michael E Barish; Stephen J Forman; Michael C Jensen
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

2.  Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.

Authors:  Wei Zhang; Xiao-guang Qiu; Bao-shi Chen; Shou-wei Li; Yun Cui; Huan Ren; Tao Jiang
Journal:  Chin Med J (Engl)       Date:  2009-06-05       Impact factor: 2.628

3.  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Authors:  J C Easaw; W P Mason; J Perry; N Laperrière; D D Eisenstat; R Del Maestro; K Bélanger; D Fulton; D Macdonald
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

4.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

5.  Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.

Authors:  Clovis O da Fonseca; Marcela Simão; Igor R Lins; Regina O Caetano; Débora Futuro; Thereza Quirico-Santos
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

6.  Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.

Authors:  Michelle A Rudek; Pamela New; Tom Mikkelsen; Surasak Phuphanich; Jane B Alavi; Louis B Nabors; Steven Piantadosi; Joy D Fisher; Stuart A Grossman
Journal:  J Neurooncol       Date:  2011-05-06       Impact factor: 4.130

7.  Thalidomide as an anti-angiogenic agent in relapsed gliomas.

Authors:  S C Short; D Traish; A Dowe; F Hines; M Gore; M Brada
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

8.  Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

9.  Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.

Authors:  W T Couldwell; D R Hinton; A A Surnock; C M DeGiorgio; L P Weiner; M L Apuzzo; L Masri; R E Law; M H Weiss
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  19 in total

Review 1.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

2.  Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.

Authors:  Warren P Mason
Journal:  Neuro Oncol       Date:  2015-07-01       Impact factor: 12.300

3.  Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions.

Authors:  Mark E Linskey; Jeffrey J Olson; Laura S Mitchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

4.  Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Authors:  Klaus Müller; Guido Henke; Sophie Pietschmann; Stefaan van Gool; Steven De Vleeschouwer; André O von Bueren; Inge Compter; Carsten Friedrich; Christiane Matuschek; Gunther Klautke; Rolf-Dieter Kortmann; Thomas Hundsberger; Brigitta G Baumert
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

Review 5.  Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.

Authors:  Alan T Yeo; Alain Charest
Journal:  J Cell Biochem       Date:  2017-05-03       Impact factor: 4.429

6.  Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?

Authors:  Andrea Horváth; Gábor Perlaki; Arnold Tóth; Gergely Orsi; Szilvia Nagy; Tamás Dóczi; Zsolt Horváth; Péter Bogner
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130

7.  Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.

Authors:  D Jay McCracken; Emma C Celano; Alfredo D Voloschin; William L Read; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2016-08-09       Impact factor: 4.130

Review 8.  An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.

Authors:  Sophie Pietschmann; André O von Bueren; Guido Henke; Michael Josef Kerber; Rolf-Dieter Kortmann; Klaus Müller
Journal:  J Neurooncol       Date:  2014-08-27       Impact factor: 4.130

9.  Controlled Drug Release and Chemotherapy Response in a Novel Acoustofluidic 3D Tumor Platform.

Authors:  Ioannis K Zervantonakis; Costas D Arvanitis
Journal:  Small       Date:  2016-03-31       Impact factor: 13.281

Review 10.  Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

Authors:  E Antonio Chiocca; Farshad Nassiri; Justin Wang; Pierpaolo Peruzzi; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.